This week, pharmaceutical company Athera Biotechnologies, completed a new share issue of SEK 55 million in which Industrifonden, Östersjöstiftelsen and the Sciety investment syndicate participated. The new capital is to be used for a clinical Phase 2 study and the company aims at being acquired by a major player after
Medtech company Likvor raises new capital for its continued expansion in Europe. They currently have about ten hospitals as clients. The company’s system is used to diagnose the dementia-like disorder, NPH. Likvor has developed a system for the monitoring of cerebrospinal spinal fluid dynamics to investigate and follow up the
Lipigon Pharmaceuticals has raised SEK 8 million in a new share issue to finance the continued pre-clinical development of pharmaceuticals within fat-related diseases, so-called lipid-related disorders. Lipid imbalance cause common diseases, such as diabetes and cardiovascular diseases, but also a number of rare diseases currently lacking sufficient treatment. Based on
Sciety is currently capitalizing a Phase II pharmaceutical company and a DNA sequencing tech company––both via private placements. The companies operate in high growth markets and raise new capital to achieve product development goals that will lead to acquisition within the next twenty-four months. Drug candidate with a
Lipid imbalances does not only cause common diseases such as diabetes and cardiovascular diseases but also various rare diseases. The pharma company Lipigon is specialised in diseases caused by lipid imbalances, with an initial focus on rare diseases that lack adequate treatments. New candidate for treatment of severe disease
CARTANA raised almost 10 million SEK in a share issue that was fully subscribed at the end of September. The company has developed reagents for analysing tissue samples in drug development processes and is based at Karolinska in Stockholm. The new capital will be used for the sale of CARTANA’s
Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.